Announced details
Ophthalmology, limbal stem cell deficiency (LSCD), corneal scarring, and refractory diseases
A substantial improvement in visual acuity was confirmed in patients with LSCD.
Business partner. We have established a collaborative framework with the company for sharing safety information and optimizing the manufacturing process for recombinant human dHGF protein.
Headquartered in New Jersey, US, Claris Biotherapeutics is a private biotech venture spun out of Harvard University in the US. The company is pursuing the development of recombinant human dHGF protein-based medicines in the ophthalmology field and conducting clinical trials in the US for limbal stem cell deficiency (LSCD) and corneal scarring.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Claris Biotherapeutics press release (https://www.clarisbio.com/news/press-releases/07-28-2026/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | CSB-001, Oremepermin alfa |
| Counterparty | Claris Biotherapeutics |
| Counterparty overview | Headquartered in New Jersey, US, Claris Biotherapeutics is a private biotech venture spun out of Harvard University in the US. The company is pursuing the development of recombinant human dHGF protein-based medicines in the ophthalmology field and conducting clinical trials in the US for limbal stem cell deficiency (LSCD) and corneal scarring. |
| Relationship with the Company | Business partner. We have established a collaborative framework with the company for sharing safety information and optimizing the manufacturing process for recombinant human dHGF protein. |
| Launch date | The pivotal trial of CSB-001 is scheduled to begin in the first half of 2027. |
| Applicable area | Ophthalmology, limbal stem cell deficiency (LSCD), corneal scarring, and refractory diseases |
| Quantitative Effects | A substantial improvement in visual acuity was confirmed in patients with LSCD. |
| Source | Claris Biotherapeutics press release (https://www.clarisbio.com/news/press-releases/07-28-2026/) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To advance late-stage clinical development, including pivotal trials, and launch preparation activities using the Series B proceeds.